Clinical Trial Update: TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of TRC105 in adults with advanced or metastatic urothelial carcinoma (and related ureteral cancers) has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of the Ureter
• Urothelial Carcinoma

Drugs mentioned

• TRC105 (carotuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Urothelial Carcinoma, Ureteral Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-03-02